SYGNIS AG

EANS-News: SYGNIS Pharma AG
SYGNIS announces last patient treated in its AXIS 2 efficacy Study

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Research & Development


Heidelberg (euro adhoc) - SYGNIS announces last patient treated in its AXIS 2
efficacy Study


Heidelberg,  03  November  2011  -  SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN
DE000A1E9B74; Prime Standard), a clinical stage biotech company researching  and
developing innovative CNS treatments, today  announced  the  completion  of  the
treatment for its randomized, double-blind study  designed  to  demonstrate  the
efficacy of AX200 for the treatment  of  patients  with  acute  ischemic  stroke
(AXIS 2). 328 patients have been treated across eight European countries.

AX200 has a dual mechanism-of-action in the treatment of acute stroke,  stopping
neuronal cell death and promoting the regeneration of the  damaged  CNS  tissue,
providing a new, first-in-class approach to treating stroke patients.

Dr. Frank Rathgeb, Chief Medical Officer of SYGNIS, commented: "We  are  pleased
to have completed treatment in our clinical phase II efficacy study and are  now
finalizing the data collection. We expect to  report  initial  findings  of  the
AXIS 2 Study towards the end of 2011".

Going forward, SYGNIS will review the options for the development and  marketing
of AX200. Possibilities include continuing development by the company itself  or
through outlicensing to external parties.  In  addition,  SYGNIS  will  consider
developing AX200 together with a partner.


About the AXIS 2 Study

The AXIS 2 Study started in mid 2009 in about  80  renowned  stroke  centres  in
Germany, Austria, Belgium, Sweden, Spain, the Czech  Republic,  Poland  and  the
Slovak Republic. The Study included 328 stroke patients, the one half  of  which
has been treated with AX200 and the other half with  a  placebo.  Patients  were
enrolled up to nine hours after suffering a stroke  and  have  been  treated  by
infusion for a period of three days. Also patients were included into  the  AXIS
2 Study, who  received  drug-based  lysis  therapy  using  rt-PA  prior  to  the
treatment with AX200. AX200 is one of the most advanced drug candidates for  the
treatment of acute stroke worldwide.


About SYGNIS Pharma

SYGNIS Pharma AG, headquartered in Heidelberg,  is  a  specialty  pharmaceutical
company listed in the Prime  Standard  of  the  Frankfurt  Stock  Exchange.  The
Company is focused on the research and development of innovative  therapies  for
the treatment of disorders of the Central Nervous System. SYGNIS´ core  projects
are currently Acute Stroke for which SYGNIS´ lead clinical programme  is  AX200,
as well as the preclinical KIBRA-project for the treatment  of  different  forms
of dementia. All these disorders are characterized by  the  fact  that,  as  the
disease progresses, nerve cells are damaged and die.  Although  there  is  great
medical demand, there are currently no  or  only  inadequate  treatment  options
available. Furthermore, a key element of the sustainable value creation  of  the
Company is the expansion of the product pipeline, which will be secured  through
its own developments as well as in-licensing and acquisitions.


For further information please contact:

SYGNIS Pharma AG

      Dr. Franz-Werner Haas
      Senior Vice President Operations
      +49 (0) 6221 454 812
   franz-werner.haas@sygnis.de

Media Contact:
      Julia Phillips
      FTI Consulting
      Tel.: +44 (0) 20 7269 7187


###

Disclaimer
Some statements included in this  press  release,  relating  neither  to  proven
financial results nor other  historical  data,  should  be  viewed  as  forward-
looking, i.e. not definite. Such statements are  mainly  predictions  of  future
results, trends, plans or goals. These statements should not  be  considered  to
be total guarantees since given their very nature they are subject to known  and
unknown risks and imponderability and can be affected  by  other  factors  as  a
consequence of which the actual results, plans and goals  of  SYGNIS  Pharma  AG
may deviate greatly from the  established  conclusions  or  implied  predictions
contained in such statements. SYGNIS does not undertake to  publicly  update  or
revise these statements in the light of new information  or  future  results  or
for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:     contact@sygnis.de
WWW:      http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English
 



Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: